Stocks and Investing Stocks and Investing
Fri, October 27, 2017
Thu, October 26, 2017
Wed, October 25, 2017
Tue, October 24, 2017
Mon, October 23, 2017

Andrew Berens Maintained (BPMC) at Buy with Increased Target to $78 on, Oct 23rd, 2017


Published on 2024-10-25 23:49:45 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $45 to $78 on, Oct 23rd, 2017.

Andrew has made no other calls on BPMC in the last 4 months.



There is 1 other peer that has a rating on BPMC. Out of the 1 peers that are also analyzing BPMC, 0 agree with Andrew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Andrew


  • Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $66 on, Wednesday, September 20th, 2017